Long-term therapy of bipolar illness.
Keck
Paul E
PE
University of Cincinnati College of Medicine, USA.
D000339:Affect / Q000187:drug effects*; D018692:Antimanic Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D002220:Carbamazepine / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D000077213:Lamotrigine; D018020:Lithium Compounds / Q000627:therapeutic use; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D018020:Lithium Compounds; D014227:Triazines; D001569:Benzodiazepines; D002220:Carbamazepine; D010890:Pirenzepine; D014635:Valproic Acid; D000077152:Olanzapine; D000077213:Lamotrigine